Triple Negative Breast Cancer
449
123
178
102
Key Insights
Highlights
Success Rate
62% trial completion
Published Results
63 trials with published results (14%)
Research Maturity
102 completed trials (23% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
13.8%
62 terminated out of 449 trials
62.2%
-24.3% vs benchmark
8%
37 trials in Phase 3/4
62%
63 of 102 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 102 completed trials
Clinical Trials (449)
MicroRNA Profiles in Triple Negative Breast Cancer
Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells